Repeated administration of D 9 -tetrahydrocannabinol (THC), the primary psychoactive constituent of Cannabis sativa, induces profound tolerance that correlates with desensitization and downregulation of CB 1 cannabinoid receptors in the CNS. However, the consequences of repeated administration of the endocannabinoid N-arachidonoyl ethanolamine (anandamide, AEA) on cannabinoid receptor regulation are unclear because of its rapid metabolism by fatty acid amide hydrolase (FAAH and cross-tolerance indicated that the behavioral effects of THC, a low efficacy CB 1 receptor agonist, were more sensitive to receptor loss than those of AEA, a higher efficacy agonist, suggesting that the expression of tolerance was more affected by the intrinsic activity of the ligand at testing than during subchronic treatment. In addition, the CB 1 receptor antagonist, rimonabant, precipitated a markedly reduced magnitude of withdrawal in FAAH À/À mice treated subchronically with AEA compared with mice treated repeatedly with THC.
INTRODUCTION
The endocannabinoid system is comprised of cannabinoid CB 1 and CB 2 receptors and endogenous ligands, including N-arachidonoyl ethanolamine (anandamide, AEA) and 2-arachidonoyl glycerol (Howlett et al, 2002) . Cannabinoids, including D 9 -tetrahydrocannabinol (THC), the primary psychoactive component of marijuana, produce a variety of pharmacological effects, including antinociception, motor disturbances, and hypothermia (Hollister, 1986; Compton et al, 1992) , which correspond to the widespread distribution of CB 1 receptors in the CNS (Herkenham et al, 1991; Glass et al, 1997) . AEA was initially shown to produce cannabinoid effects (Smith et al, 1994) that were short lived because of its rapid degradation (Willoughby et al, 1997) . Initial observations on the function of AEA have been extended using genetically modified mice lacking fatty acid amide hydrolase (FAAH), the principal enzyme responsible for degradation of AEA and other fatty acid amides (Cravatt et al, 2001) . Administration of AEA to FAAH À/À mice produced antinociception, catalepsy, locomotor inhibition, and hypothermia that persisted 6-8 h. AEA-mediated effects were reversed by the CB 1 receptor antagonist SR141716A (rimonabant) (Cravatt et al, 2001 ) and dual FAAH À/À /CB 1 receptor À/À mice were impervious to the analgesic, cataleptic, and hypothermic effects of AEA (Wise et al, 2007) , indicating that these effects are mediated through CB 1 receptors. In addition to this enhanced sensitivity to the pharmacological effects of exogenously administered AEA, FAAH À/À mice were found to exhibit a hypoalgesic phenotype (Cravatt et al, 2001; Lichtman et al, 2004b) .
Importantly, FAAH
À/À mice exhibit normal CB 1 receptor expression despite constitutively elevated levels of endogenous fatty acid amides (Cravatt et al, 2001) .
CB 1 receptors belong to the G-protein-coupled receptor superfamily and activate primarily Ga i/o , resulting in inhibition of adenylyl cyclase, activation of A-type and inwardly rectifying potassium channels, inhibition of N-and P/Q-type calcium channels, and stimulation of MAP kinase (Howlett et al, 2002) . Repeated exposure to THC or synthetic cannabinoid agonists (eg, WIN55, CP55, 940) in rodents produces desensitization of cannabinoid-mediated G-protein activity and inhibition of adenylyl cyclase, as well as CB 1 receptor downregulation (Sim-Selley, 2003; Martin et al, 2004) . Treatment paradigms that produce these cellular adaptations are also associated with the development of tolerance to in vivo cannabinoidmediated effects Lichtman and Martin, 2005) . Rimonabant administration precipitates withdrawal effects in mice treated chronically with cannabinoid receptor agonists (Tsou et al, 1995; Cook et al, 1998) that is accompanied by increased cAMP in the cerebellum (Hutcheson et al, 1998; Rubino et al, 1998; Tzavara et al, 2000) . The relevance of these adaptations is suggested by the findings that repeated THC use produces tolerance and dependence in human beings (Jones et al, 1976; Jones et al, 1981; Budney and Hughes, 2006) as well as CB 1 receptor downregulation in specific brain regions (Villares, 2007) . It is not clear whether subchronic AEA administration regulates CB 1 receptors in a similar manner as THC and synthetic cannabinoids. AEA administration has been reported to produce an inconsistent and small degree of tolerance and dependence (Pertwee et al, 1993; Aceto et al, 1998) , and treatment with AEA or the AEA analog methanandamide either reduced or did not alter levels of cannabinoid receptors and receptor-mediated G-protein activity (Romero et al, 1995; Romero et al, 1999; Rubino et al, 2000) . Thus, results to date have been inconclusive and interpretation is complicated by the instability of AEA in the presence of endogenous FAAH (Willoughby et al, 1997) . FAAH À/À mice provide a model in which to examine the effects of repeated AEA administration on CB 1 receptor regulation and in vivo activity. Earlier studies, while providing variable results, suggest that THC and AEA might differentially regulate CB 1 receptors in the CNS. To test this hypothesis, we investigated whether FAAH À/À mice that were repeatedly administered equivalent maximally effective doses of AEA or THC would show differential tolerance to cannabinoid-mediated in vivo effects, signs of rimonabant-precipitated withdrawal, and receptor desensitization and downregulation.
MATERIALS AND METHODS

Subjects
The subjects were male C57Bl/6J mice (Jackson Laboratory, Bar Harbor, ME) as well as male and female FAAH À/À and FAAH + / + mice backcrossed for at least 13 generations onto a C57Bl/6J background. Subjects weighed between 20 and 30 g and were housed four mice per cage in a temperaturecontrolled (20-221C) facility, with food and water available ad libitum. All animal protocols were approved by the Virginia Commonwealth University Institutional Animal Care and Use Committee. 
Drugs and Chemicals
Repeated Drug Administration
All subchronic dosing was administered through the subcutaneous route of administration given twice daily (0800 and 1600 hours) with vehicle (emulphor : ethanol : saline in a ratio of 1 : 1 : 18), THC (50 mg/kg), or AEA (50 mg/kg) on 5 consecutive days. On the 6th day, only the 0800 hours injection was administered. These doses of AEA and THC were selected because in preliminary experiments (data not shown) they produced maximal antinociceptive effects in control mice (also see Figures 1, top panel and Figure 3 , top panel).
In Vivo Measures
Nociceptive behavior was assessed in the tail withdrawal test using a 521C water bath, a temperature that does not produce FAAH À/À phenotypic hypoalgesic responses (Cravatt et al, 2001) . The tail withdrawal data were expressed as a percentage of maximal possible effect (%MPE ¼ (withdrawal latency-baseline withdrawal)/ (10 s-baseline withdrawal). Body temperature was obtained by inserting a digital thermometer (Fisher Scientific, Pittsburgh, PA) 2 cm into the anus and recorded to the nearest 0.11C. Catalepsy was scored as positive when mice maintained a rigid posture for 10 s in the bar test (Cravatt et al, 2001 ).
Cumulative Dose-Response Curves
Twenty-four hours after the final subchronic injection, a cumulative dosing regimen was used to determine the doseresponse relationships for antinociception, hypothermia, and hypomotility. Subjects received increasing doses of THC or AEA every 40 min with end points assessed 30 min after each injection, as specified in the results. Several experiments were conducted that included control mice that received repeated vehicle injections every 40 min, with end points assessed 30 min to ensure that no vehicle effects occurred.
Rimonabant-Precipitated Withdrawal
Subjects (n ¼ 36) were treated with vehicle, AEA, or THC according to the repeated administration schedule described above. On day 6, mice were injected with the final subchronic treatment, and placed in a Plexiglas observation chamber (21.5 Â 21.5 Â 15 cm); 30 min later, subjects were administered rimonabant (10 mg/kg; i.p.) and scored for paw tremors (shaking of one or both paws) and head shaking/twitching (minimum of two quick, successive head movements in a counterclockwise/clockwise manner and righted to the original position). Mice were observed for 1 h and scored in 5-min bins, separated by 5-min break periods.
Comparison of THC Brain Levels Between Bolus and Cumulative Dosing Procedures
Acute THC brain and blood levels were determined 30 min after single bolus administration of 3, 10, or 30 mg/kg THC or 30 min after the final injection of cumulative dosing of 10, 30, or 56 mg/kg THC. The mice were decapitated 20 min after drug administration and the blood was collected in heparinized (Elkins-Sinn, Cherry Hill, NJ) tubes. The THC extraction procedure and quantification procedure were conducted as described earlier (Wilson et al, 2006) . A total of 50 ng of deuterated THC (Radian Corporation, Austin, TX) was added to the blood sample, brain homogenate, and calibrators (blank mouse whole blood and homogenized brain) as an internal standard. After an equilibration period, 2.5 ml cold acetonitrile (HPLC grade, Fisher Scientific, Raleigh NC) was added drop-wise while vortexing. The samples were centrifuged at 2500 rpm for 15 min to pelletize solids and stored in a freezer (À201C) overnight to separate the acetonitrile and aqueous layers. The acetonitrile layer was then removed and evaporated to dryness under nitrogen. The THC/deuterated THC was resolublized in 0.1 ml methanol (HPLC grade, Fisher Scientific) and quantified through LC-MS (Quattro II). Ions analyzed in single ion monitoring mode were 315 and 118 for THC and deuterated THC, respectively. A calibration curve was constructed for each assay based on linear regression using the peak-area ratios of THC to deuterated THC of the extracted calibration samples.
Agonist-Stimulated [ 35 S]GTPcS Autoradiography
Mice were treated subchronically with vehicle, AEA, or THC as described above. Twenty-four hours after the final injection, brains were removed and frozen in isopentane (À301C). Coronal sections (20 mm) in regions of interest were cut on a cryostat (À201C) and collected on subbed slides. Slides were desiccated overnight at 41C and stored at À801C. Assays were conducted as published (Sim-Selley and Martin, 2002) . Slides were incubated in TME buffer (50 mM Tris-HCl, 3 mM MgCl 2 , 0.2 mM EGTA, 100 mM NaCl) for 10 min, then transferred to TME buffer + 0.5% BSA containing 2 mM GDP and 10 mU/ml adenosine deaminase for 20 min. Sections were then incubated for 2 h in 0.04 nM [ 35 S]GTPgS, 2 mM GDP, 10 mU/ml adenosine deaminase, and maximally effective concentrations of WIN55,212-2 (10 mM) or AEA (20 mM) in TME buffer + BSA at 251C. Slides were rinsed in Tris buffer (2 Â 2 min at 41C, 50 mM, pH 7.4) and ddH 2 O (30 s, 41C), dried, and placed in cassettes with 14 C microscales and Kodak Biomax MR film for 24 h. 3 H]WIN55,212-2 binding was conducted as published (Breivogel et al, 1999) . Sections were collected as described above. Slides were incubated in assay buffer (20 mM HEPES, 1 mM MgCl 2 , and 0.5% w/v BSA, pH 7.0) for 20 min at 301C. Sections were then incubated in 1 nM [ assay buffer (80 min, 301C) in the absence or presence of 1 mM unlabeled WIN55,212-2 to assess total and nonspecific binding, respectively. Slides were washed in assay buffer (4 Â 10 min each, 251C) and dipped in ddH 2 O (41C). Slides were dried and exposed to Kodak Biomax MS film for 6 weeks with 3 H microscales.
Agonist-Stimulated [ 35 S]GTPcS Binding in Membranes
Assays were conducted as published earlier (Sim-Selley et al, 2006) . Spinal cords were removed, rapidly frozen, and stored at À801C. For each experiment, tissue was thawed and homogenized in membrane buffer (Tris-HCl, pH 7.4, 3 mM MgCl 2 , and 1 mM EDTA). Homogenates were centrifuged at 50 000 g for 10 min at 41C, the supernatant was discarded, and the pellet re-suspended in membrane buffer. Centrifugation was repeated, the pellet re-suspended in TME buffer, and protein concentration determined. Membranes were pretreated with adenosine deaminase (10 mU/ml) for 15 min at 301C before assay. Membrane protein (10 mg) was incubated in TME with 0.1% BSA, 30 mM GDP, 0.1 nM [ 35 S]GTPgS, and varying concentrations of WIN55,212-2 or AEA for 2 h at 301C. Non-specific binding was determined with 10 mM unlabeled GTPgS and basal binding was determined in the absence of agonist. The incubation was terminated by rapid filtration through GF/B glass fiber filters and three rinses with ice-cold Tris-HCl, pH 7.4. Bound radioactivity was determined by liquid scintillation spectrophotometry after extraction of filters in ScintiSafe Econo-1 scintillation fluid.
Data Analysis
All in vivo data were analyzed using one-or two-way analyses of variance (ANOVA), followed by Tukey post hoc tests when appropriate. As no significant sex differences were observed in any of the studies, this factor was collapsed in all analyses. The p-values of o0.05 were considered significant. The ED 50 values with 95% confidence intervals (CI) were calculated using standard linear regression analysis of the dose-response curve. Potency ratios with 95% CI were calculated by comparing the potency between two treatments, as described by Colquhoun (1971) . Treatments that had potency ratios that did not include a ratio of 1 in the 95% CI were considered significant.
Autoradiographic analysis was performed using NIH ImageJ software. Data are reported as mean ± SEM of triplicate sections from 4 to 6 (study 1) or 8 to 12 (study 2) brains/group. H]WIN55,212-2 binding). In study 1, a two-way ANOVA and post hoc tests were used to compare the three Dunnett's treatment groups (vehicle-, THC-, and AEA-treated) across genotype; in study 2, a two-way ANOVA examined an overall effect of treatment across brain region, whereas one-way ANOVAs (with post hoc Dunnett's tests) compared the FAAH À/À treatment groups within each region. Concentration-effect curves in membranes were fit by non-linear regression analysis to obtain E max and EC 50 values using GraphPad Prism 4.0 software. The significance of concentration-effect curves was determined by two-way ANOVA; significant differences in E max and EC 50 values were determined by one-way ANOVA with a post hoc Dunnett's test.
RESULTS
Behavioral Measures
Cumulative dosing of THC produces identical doseresponse curves in naive FAAH À/À and FAAH + / + mice. In initial experiments, we evaluated the feasibility of evaluating the dose-response relationship of THC using a cumulative dosing regimen in which mice were dosed with increasing amounts of drug and tested repeatedly across the same session. The data presented in Table 1 compare the resulting blood and brain levels of THC between mice subjected to cumulative dosing and single bolus dosing. Both types of injection regimens led to equivalent levels of THC in both blood and brain, as indicated by a lack of significance between injection regimens. Next, we compared the dose-response relationship of THC after cumulative dosing between FAAH + / + and FAAH À/À mice. As previously reported using separate groups of mice (Cravatt et al, 2001) , THC was equipotent and elicited similar doseresponse profiles for antinociception (potency ratio (95% CI)) values: 1.1 (0.8-1.5); Figure 1 Evaluation of subchronic dosing of THC and AEA on the dose-response relationship of AEA in FAAH À/À mice. Repeated administration of two daily injections of AEA (50 mg/kg) for 5.5 days resulted in rightward shifts in the dose-response relationships to the antinociceptive (Figure 3 Figure 4 , top panel; t 10 ¼ 5.3, p ¼ 0.001), but produced no changes in the number of head twitches (Figure 4 , bottom panel). In addition, the magnitude of the rimonabant precipitated paw flutters after subchronic AEA administration was smaller than after subchronic THC (AEA mean ± SEM ¼ 74 ± 13; THC mean ± SEM ¼ 222 ± 41).
Agonist-Stimulated [ 35 S]GTPcS Binding
Desensitization of cannabinoid-stimulated G-protein activity usually occurs after repeated cannabinoid treatment regimens that produce tolerance (Sim- Selley, 2003 animals. Densitometric analysis of caudate-putamen, hippocampus, and cerebellum ( Figure 5) 
Agonist-Stimulated [ 35 S]GTPcS Binding in Spinal Cord Membranes
To determine the effect of subchronic THC or AEA administration on cannabinoid receptor-mediated G-protein activation in spinal cord, a CNS region that is relevant for antinociception, agonist-stimulated [ À/À animals treated with THC, whereas AEA treatment minimally affected receptor levels or receptor-mediated G-protein activity. This conclusion is clearly illustrated in Figure 9 , in which data from THC-and AEA-treated mouse brains are expressed as Table 4 . percentage of vehicle control. These results are also similar to those obtained in the spinal cord, suggesting that THC and AEA differentially regulate cannabinoid receptors throughout the CNS.
DISCUSSION
The results of this study revealed that repeated administration of AEA in FAAH À/À mice produced different neuroadaptations Figure 2 , bottom panel; Table 2 ). In contrast, AEA doseresponse curves for antinociception and hypothermia were shifted only threefold in FAAH À/À mice, regardless of whether the mice were treated subchronically with either THC or AEA. However, the AEA dose-response curve for catalepsy in FAAH À/À mice was shifted further to the right after repeated administration of THC than repeated administration of AEA. Thus, in vivo tolerance was found in FAAH À/À mice treated repeatedly with AEA or THC, but the magnitude of tolerance expressed depended more on the test drug than the drug administered subchronically, although catalepsy seems to be an exception.
As previously reported (Cravatt et al, 2001) , FAAH À/À and FAAH + / + mice displayed similar sensitivity to the acute effects of THC. Here, using the cumulative dosing procedure yielded similar ED 50 values for antinociception, catalepsy, and hypothermia as previously reported when separate groups of mice were given a single bolus injection. In addition, cumulative dosing and single bolus injections led to similar brain and blood levels of THC (see Table 1 ). Collectively, these findings indicate the following two conclusions: (1) cumulative dosing and single bolus dosing lead to similar blood and brain levels of THC at the time of in vivo testing and (2) the THC cumulative dose-response curves for antinociception, catalepsy, and hypothermia are virtually identical between FAAH + / + and FAAH À/À mice. Thus, the impact of repeated THC or AEA administration on tolerance was evaluated by using cumulative dosing procedure to derive dose-response relationships.
Previous studies showed that brains from FAAH À/À and FAAH + / + mice exhibited similar levels of CB 1 receptors as assessed in membrane homogenates prepared from whole brain (Cravatt et al, 2001) . This study extended those findings using autoradiography to show that the levels of CB 1 receptors and receptor-mediated activity do not differ between FAAH À/À and FAAH + / + mice in several regions that express CB 1 receptors and mediate cannabinoid effects.
Moreover, THC treatment attenuated receptor binding and receptor-mediated G-protein activity similarly in FAAH À/À and FAAH + / + mice. These findings suggest that elevated AEA levels do not affect acute CB 1 receptor activity or regulation in response to chronic THC. The present results differ somewhat from a previous study showing that 15 day AEA administration in FAAH-competent rats produced desensitization of cannabinoid-mediated G-protein activity in the absence of alterations in receptor binding (Rubino et al, 2000) . Differences in both species and treatment duration could have contributed to the discrepancy with the present results.
Subchronic administration of AEA to FAAH À/À mice led to approximately threefold decreases in the potency of its antinociceptive, cataleptic, and hypothermic effects. In contrast, a much more profound tolerance was found after repeated THC treatment in FAAH À/À and FAAH + / + mice. Both genotypes developed a similar degree of tolerance to the analgesic and cataleptic effects of THC, but FAAH À/À mice exhibited a greater magnitude of tolerance to the hypothermic effects of THC than FAAH + / + mice. This pattern of findings is consistent with the hypothesis that adaptation of CB 1 receptors and/or downstream signaling responses after repeated cannabinoid administration has a predominant function in the dampening of cannabinoidmediated in vivo effects rather than through effects on endocannabinoids directly.
Earlier studies have shown that AEA-treated mice exhibit cross-tolerance to the cataleptic, hypolocomotor, analgesic, and hypothermic effects of THC (Fride, 1995) . In contrast, animals treated with THC exhibit cross-tolerance to only certain AEA-mediated effects, for example antinociception (Welch, 1997) , but not hypothermia (Pertwee et al, 1993) . In fact, an assessment of cross-tolerance between THC and AEA and its analogs revealed that cross-tolerance was dependent on the task as well as the particular AEA analog tested (Wiley et al, 2005) . This study used FAAH À/À mice to examine cross-tolerance in both THC-and AEA-treated mice. FAAH À/À mice treated subchronically with AEA displayed profound cross-tolerance to THC, with the greatest decrease in efficacy or potency to THC-mediated cataleptic effects. On the other hand, FAAH À/À mice treated repeatedly with THC displayed cross-tolerance to the behavioral effects of AEA, with approximately threefold decreases in the potency to its antinociceptive and hypothermic effects, although a greater decrease in the potency or efficacy of AEA-mediated cataleptic effects was found. These findings taken together suggest that the expression of tolerance is more greatly affected by the specific ligand used during testing than the ligand administered throughout the development of tolerance. In other words, testing with a low efficacy ligand, such as THC, revealed greater tolerance and cross-tolerance than a higher efficacy ligand (eg, AEA) and, therefore, perhaps greater sensitivity to receptor loss, similarly to previous findings at the level of CB 1 receptor signaling (Breivogel et al, 2003; Selley et al, 2004) . A similar relationship between efficacy of the test ligand and sensitivity to cross-tolerance has been reported for m-opioid receptor-mediated antinociception (Paronis and Holtzman, 1992) . However, further experiments with multiple agonists differing in intrinsic efficacy will be required to definitively determine whether this relationship holds true for cannabinoid receptors. Nonetheless, the present results show that subchronic administration of AEA produces less tolerance to the effects of subsequently administered AEA, compared with the magnitude of tolerance observed with subchronic THC administration and subsequent testing with THC.
Subchronic administration of maximally effective doses of THC produced similar magnitudes of CB 1 receptor desensitization and downregulation in FAAH + / + and FAAH À/À mice, as previously reported in various rodent strains using a variety of treatment paradigms (Sim- Selley, 2003) . The THC brain levels resulting from 50 mg/kg THC were 1072±156 ng/g of tissue or roughly equivalent to those after 5 mg/kg of intravenously administered THC (Wilson et al, 2006) . However, an equi-active dose of AEA administered subchronically did not alter CB 1 receptors or activity in FAAH + / + mice, which was predicted due to the instability of AEA in these mice. Surprisingly, in FAAH À/À mice, AEA treatment did not significantly reduce either CB 1 receptor levels or receptor-mediated G-protein activity in most CNS regions evaluated. The mechanism underlying differential cannabinoid receptor regulation by THC vs AEA is not clear. Both THC and AEA are partial agonists, although AEA has higher intrinsic efficacy compared with THC (Breivogel et al, 1998) . Previous studies showed that although treatment with equi-active doses of THC or WIN55,212-2, a full agonist, produced desensitization and downregulation, THC treatment produced significantly greater desensitization than WIN55,212-2 in a number of regions (Sim- Selley and Martin, 2002) . This finding is consistent with the present results and suggests that low efficacy agonists might produce greater receptor adaptation because they must occupy a higher percentage of total receptors to produce equivalent effects. However, comparison of repeated treatments with multiple agonists of varying intrinsic efficacies would be necessary to confirm this hypothesis. It is also possible that different agonists can differentially induce receptor interaction with b-arrestin to produce varying levels of desensitization, as suggested in previous studies (Bohn et al, 2004; Breivogel et al, 2008) .
Rimonabant-precipitated withdrawal is used to assess cannabinoid dependence (Lichtman and Martin, 2002) . In this study, rimonabant elicited profound somatic withdrawal signs in FAAH À/À and + / + mice treated subchronically with THC, whereas FAAH À/À mice treated with AEA displayed a greatly reduced withdrawal response. The function of cannabinoid receptor desensitization and/or downregulation in withdrawal is not clear, but the results are consistent with the general finding that repeated AEA treatment did not produce significant adaptation, whereas THC treatment produced both desensitization and downregulation of CB 1 receptors. Withdrawal after rimonabant administration in cannabinoid-treated animals is often associated with increased cAMP activity (Hutcheson et al, 1998; Rubino et al, 1998; Tzavara et al, 2000) , suggesting that fewer downstream adaptations also occur after AEA as compared with THC treatment, although this hypothesis will have to be confirmed in future studies. Nevertheless, diminished dependence elicited by subchronic AEA in FAAH À/À mice is consistent with lack of dependence liability of the FAAH inhibitor, URB597 (Schlosburg et al, 2009 ).
Cannabinoids have generated interest for treatment of a number of disorders, but their therapeutic potential is limited by unwanted side effects and the development of tolerance and dependence with repeated use. An alternate approach is to increase levels of endogenous cannabinoids by administering inhibitors of their degradative enzymes. Piomelli and colleagues initially reported the development of URB532 and URB597 (Kathuria et al, 2003) , FAAH inhibitors that produced anxiolytic and analgesic effects in the absence of catalepsy, hypothermia, or appetite stimulation. Subsequent studies have shown that several FAAH inhibitors produce analgesia in a variety of pain models (Lichtman et al, 2004a; Jayamanne et al, 2006) , further generating interest in the therapeutic potential of these compounds. The current results indicate that increasing AEA produces less cellular adaptation and associated dependence and less tolerance to its own effects than administration of THC, and further support the possible clinical usage of FAAH inhibitors.
